JP2024001073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024001073A5 JP2024001073A5 JP2023165289A JP2023165289A JP2024001073A5 JP 2024001073 A5 JP2024001073 A5 JP 2024001073A5 JP 2023165289 A JP2023165289 A JP 2023165289A JP 2023165289 A JP2023165289 A JP 2023165289A JP 2024001073 A5 JP2024001073 A5 JP 2024001073A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 12
- 102100034256 Mucin-1 Human genes 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 3
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023165289A JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/058036 WO2019083506A1 (en) | 2017-10-24 | 2017-10-24 | ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF |
| JP2020543460A JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
| JP2023165289A JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Division JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024001073A JP2024001073A (ja) | 2024-01-09 |
| JP2024001073A5 true JP2024001073A5 (cg-RX-API-DMAC7.html) | 2024-04-24 |
Family
ID=66247577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Active JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
| JP2023165289A Pending JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Active JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3700936A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7358367B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102608763B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111479828B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017436815B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020008001A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3078812A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274202A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004220A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019083506A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008001A2 (pt) * | 2017-10-24 | 2020-10-20 | Go Therapeutics, Inc. | anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica. |
| EP4188432A4 (en) * | 2020-07-31 | 2024-08-21 | R.P. Scherer Technologies, LLC | ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF |
| AU2022333837A1 (en) * | 2021-08-27 | 2024-03-14 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
| AU2022420709A1 (en) * | 2021-12-21 | 2024-08-01 | Merus N.V. | Binding domains against cancer-associated muc1 |
| CN114099685B (zh) * | 2022-01-27 | 2022-06-21 | 中国农业大学 | 抑制muc1表达和糖基化修饰的物质在降低抗乳腺癌药物耐药性中的应用 |
| AU2024251169A1 (en) * | 2023-04-13 | 2025-10-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to egfr and muc1, drug conjugate thereof, and medical use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020146750A1 (en) * | 2000-03-30 | 2002-10-10 | Hoogenboom Hendricus R.J.M. | Mucin-1 specific binding members and methods of use thereof |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2008040362A2 (en) * | 2006-10-04 | 2008-04-10 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| EP2014302A1 (en) * | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
| CN101978054B (zh) * | 2007-12-05 | 2013-05-29 | 协和发酵麒麟株式会社 | 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体 |
| EP2351777B1 (en) * | 2008-10-28 | 2015-10-28 | Shionogi&Co., Ltd. | Anti-muc1 antibody |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015120180A1 (en) * | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| EP3150634B1 (en) * | 2014-04-28 | 2020-04-22 | Medicinal Chemistry Pharmaceuticals Co., Ltd. | Anti-muc1 antibody or antigen-binding fragment thereof, and uses thereof |
| BR112020008001A2 (pt) * | 2017-10-24 | 2020-10-20 | Go Therapeutics, Inc. | anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica. |
-
2017
- 2017-10-24 BR BR112020008001-2A patent/BR112020008001A2/pt unknown
- 2017-10-24 JP JP2020543460A patent/JP7358367B2/ja active Active
- 2017-10-24 AU AU2017436815A patent/AU2017436815B2/en active Active
- 2017-10-24 EP EP17929557.1A patent/EP3700936A4/en active Pending
- 2017-10-24 WO PCT/US2017/058036 patent/WO2019083506A1/en not_active Ceased
- 2017-10-24 KR KR1020207014390A patent/KR102608763B1/ko active Active
- 2017-10-24 CA CA3078812A patent/CA3078812A1/en active Pending
- 2017-10-24 MX MX2020004220A patent/MX2020004220A/es unknown
- 2017-10-24 CN CN201780097773.8A patent/CN111479828B/zh active Active
- 2017-10-24 KR KR1020237040745A patent/KR102832078B1/ko active Active
-
2020
- 2020-04-23 IL IL274202A patent/IL274202A/en unknown
-
2023
- 2023-09-27 JP JP2023165289A patent/JP2024001073A/ja active Pending